US researchers have revealed(link is external) the identity of molecules on the surface of cancer cells which allow the body’s immune system to identify and destroy them.
The research could lead to a new generation of immunotherapies that are far more effective than those currently in use, that could target a range of cancers.
“This is a huge breakthrough,” said Cancer Research UK’s Dr Sergio Quezada, who works at UCL in London and was not involved in the research.
“The researchers were looking for ‘signatures’ on the surface of cancer cells associated with response to current immunotherapies, but their findings go further than that. They’ve actually discovered molecular motifs that will inform the development of the next generation of therapies,” he added.
The researchers, led by a team at the Memorial Sloan Kettering Cancer Centre in New York, analysed cancer DNA from 64 melanoma patients who had been treated with an immunotherapy drug called ipilimumab, half of whom had responded to the drug.
Ipilimumab works by switching on the body’s immune system to attack their cancer, but – for unknown reasons – it only works effectively in a minority of patients.
“We’ve been using a drug that empirically was found to be quite effective, and yet we didn’t have a detailed understanding of how it was working in people,” said Memorial Sloan Kettering’s Dr Jedd Wolchok.
Having analysed the patients’ cancer DNA, the researchers used sophisticated software to look for genetic mutations in the cancer cells that could predict whether patients had, or hadn’t, responded to the drug.
In doing so, they uncovered a series of genetic mutations in some of the patients that caused the cancer cells to produce short stretches of protein molecules, called peptide antigens, that make cancerous cells visible to immune response.
Tantalisingly, it appears that these mutations cause the antigens to mimic small parts of proteins produced by bacteria and viruses, explaining why they are so effective at triggering the immune response – although the researchers say more research will be needed to confirm this.
The discovery is “big, big news” for immunotherapy researchers says Cancer Research UK’s Dr Quezada. “This is the first time we’ve had an idea of what the immune system actually ‘sees’ on a tumour. Until now, it’s been hot topic of debate,” he said.
The Latest on: Immunotherapies
via Google News
The Latest on: Immunotherapies
- Domain Therapeutics Bags €39M to Block GCPRs in Cancer Immunotherapyon May 13, 2022 at 7:13 am
Domain Therapeutics, a biopharmaceutical company in France and Canada developing cancer immunotherapies targeting G protein-coupled receptors (GPCRs), has closed a €39M ($42M) Series A financing round ...
- University of Maryland Medical Center hopes new Baltimore cancer center will advance treatment, careon May 13, 2022 at 5:00 am
What if in the next few years patients with cancer in their lungs or blood could sit in a chair, get an infusion of their own modified cells to wipe out their cancer and go home? Cancer researchers ...
- HCW Biologics Reports First Quarter 2022 Financial Results and Recent Business Highlightson May 13, 2022 at 4:19 am
HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age ...
- Zacks Investment Research Lowers PDS Biotechnology (NASDAQ:PDSB) to Sellon May 13, 2022 at 4:09 am
According to Zacks, “PDS Biotechnology Corp. is an immuno-oncology company. It is focused on developing a pipeline of clinical-stage immunotherapies to treat cancers, including head and neck cancer, ...
- Marker Therapeutics Reports Q1 2022 Operating and Financial Resultson May 13, 2022 at 4:00 am
Topline readout of Phase 2 AML trial Group 2 active disease anticipated in Q2 2022 Company plans to file INDs in lymphoma and pancreatic cancer by year end, with clinical trials to be initiated in ...
- Neoleukin Therapeutics (NASDAQ:NLTX) Cut to “Hold” at Zacks Investment Researchon May 13, 2022 at 2:50 am
According to Zacks, “Neoleukin Therapeutics Inc. is a biopharmaceutical company. It is engaged in creating next generation immunotherapies using de novo protein design technology. The company’s ...
- Xenetic Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Updateon May 12, 2022 at 1:11 pm
The Company’s interventional DNase based oncology platform is aimed at improving outcomes of existing treatments, including immunotherapies. The exclusive license to CLS’ intellectual property for ...
- Evaxion Biotech successfully produces personalized cancer immunotherapies in phase 1/2a trial for EVX-02on May 11, 2022 at 3:30 am
Evaxion Biotech A/S, a clinical-stage biotechnology, announced that it has successfully produced all batches of personalized cancer immunotherapies for all patients enrolled in the phase 1/2a clinical ...
- Evaxion Biotech Announces Successful Production of Personalized Cancer Immunotherapies in Phase 1/2a Clinical Trial for EVX-02on May 10, 2022 at 5:49 am
COPENHAGEN, Denmark, May 10, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to ...
- Discovery provides critical clues to why many immunotherapies trigger dangerous side effectson May 5, 2022 at 6:43 am
Their findings, published recently in Nature, provide critical clues to why many immunotherapies trigger dangerous side effects-;and point to a better strategy for treating patients with solid tumors.
via Bing News